Market News / Story
Agenus Inc. (AGEN) Wins First Marketing OKs for BOT+BAL in Armenia
·
Agenus said Armenia granted the first marketing authorizations for botensilimab plus balstilimab in previously treated MSS metastatic colorectal cancer without active liver metastases. The conditional approvals are valid one year from Oct. 2, 2026. Material Details #DetailAI Analyst View1First approvals for BOT+BAL worldwideDe-risks the program with initial regulatory validation; can catalyze access and visibility.2Indication: MSS mCRC, no active liver metsTargets a…
Related stories
India’s central bank hikes rates for the first time since 2023 as inflation risks buildRead story summary
The Reserve Bank of India on Wednesday raised interest rates for the first time since 2023, joining several major central banks in tightening monetary policy to arrest accelerating inflation. The central bank increased the benchmark repo rate by 25 basis points to a 1-year high of 5.50%, in line with expectations of economists polled by Reuters. India’s ...
VIEW SOURCE